Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2022 16:30 ET | Source: Atreca, Inc.

Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as Drugs

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
November 08, 2021 16:30 ET | Source: Atreca, Inc.

Atreca to Present at Upcoming Virtual Investor Conferences

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
November 02, 2021 08:30 ET | Source: Atreca, Inc.

Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
October 21, 2021 08:00 ET | Source: Atreca, Inc.

Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria

SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
October 01, 2021 08:00 ET | Source: Atreca, Inc.

Atreca Announces Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
September 08, 2021 16:30 ET | Source: Atreca, Inc.

Atreca to Present at Upcoming Virtual Investor Conferences

SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
August 11, 2021 16:05 ET | Source: Atreca, Inc.

Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
August 04, 2021 16:30 ET | Source: Atreca, Inc.

Atreca to Present at Upcoming Virtual Investor Conferences

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
July 29, 2021 07:00 ET | Source: Atreca, Inc.

Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors

Completed dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed Disease control associated with ATRC-101 target expression; preliminary...
July 26, 2021 16:30 ET | Source: Atreca, Inc.

Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101

SAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...